Manohar Prasanth, Loh Belinda, Athira Sudarsanan, Nachimuthu Ramesh, Hua Xiaoting, Welburn Susan C, Leptihn Sebastian
Zhejiang University-University of Edinburgh Institute, Zhejiang University, Haining, China.
The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Microbiol. 2020 Jun 26;11:1434. doi: 10.3389/fmicb.2020.01434. eCollection 2020.
Secondary bacterial infections manifest during or after a viral infection(s) and can lead to negative outcomes and sometimes fatal clinical complications. Research and development of clinical interventions is largely focused on the primary pathogen, with research on any secondary infection(s) being neglected. Here we highlight the impact of secondary bacterial infections and in particular those caused by antibiotic-resistant strains, on disease outcomes. We describe possible non-antibiotic treatment options, when small molecule drugs have no effect on the bacterial pathogen and explore the potential of phage therapy and phage-derived therapeutic proteins and strategies in treating secondary bacterial infections, including their application in combination with chemical antibiotics.
继发性细菌感染在病毒感染期间或之后出现，可导致不良后果，有时还会引发致命的临床并发症。临床干预措施的研发主要集中在主要病原体上，而对任何继发性感染的研究都被忽视了。在这里，我们强调继发性细菌感染，特别是由耐药菌株引起的感染对疾病结局的影响。我们描述了在小分子药物对细菌病原体无效时可能的非抗生素治疗选择，并探讨了噬菌体疗法以及噬菌体衍生的治疗性蛋白质和策略在治疗继发性细菌感染中的潜力，包括它们与化学抗生素联合应用的情况。
